Dermatology Times: May 25, 2025

12345678910111213141516
Across
  1. 6. A non-systemic treatment for CHE that involves controlled light exposure
  2. 10. An oral JAK inhibitor studied for targeting both Th1 and Th2 in CHE treatment
  3. 11. An oral retinoid shown to outperform phototherapy in the ALPHA study for CHE
  4. 12. A topical pan-JAK inhibitor approved in the EU for CHE treatment
  5. 14. The excessive thickening of the outer skin layer, common in CHE lesions
  6. 15. A known adverse effect of long-term topical corticosteroid use in skin treatment
  7. 16. The proximal daily activity limitations score used in the HEIS measurement tool
Down
  1. 1. CHE often presents with more than 1 of these, complicating diagnosis and treatment
  2. 2. 1 in 5 patients attributed CHE to this kind of exposure or hazard
  3. 3. A descriptive term for the skin affected by CHE, often cracked too
  4. 4. Topical treatment with associated phobia and concerns over long-term skin damage
  5. 5. Patients with CHE may escalate to this level of therapy after failing topicals
  6. 7. (Abbreviation) A validated scale that measures the quality of life impact of CHE
  7. 8. A study evaluating real-world physician-reported outcomes of CHE management
  8. 9. (Abbreviation) A class of drugs that block Janus kinase signaling and may be used off-label for CHE
  9. 13. A multinational study investigating the burden and prevalence of CHE